retatrutide latest news Phase III study demonstrates 30% weight loss 🚨Breaking: Retatrutide's first Phase 3

Moreover, the in vitro results depicted that chloroform extract depicted the maximum inhibitory strength against DPP-IV (IC 50 value = 221.58 g/ml), whereas the hexane extract expressed the minimum inhibitory potential

A 72-week, double-blind phase 2 trial showed that once-daily administration of semaglutide had a significant therapeutic effect on NASH (193)

The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in late 2024, which ended the shortage-list justification that most large-scale compounding relied on

PMC12313605 10

Additionally, no association was observed between the use of GLP-1 RAs and the incidence of sunburn, herniated intervertebral discs, traffic accidents, or pneumonia